Patent US3945889A successfully refreshed from Google Patents.
US3945889A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Preparation of human placental hyaluronidase
Assignee: Tanabe Pharma Corp
•
Filing: 1974-08-27
•
Granted: 1976-03-23
•
Expires: 1994-08-27
Abstract
Abstract Human placental hyaluronidase preparation is prepared by extracting hyaluronidase from human placenta with an aqueous alkaline solution, harvesting globulin fraction from the extract, selectively adsorbing hyaluronidase contained in the fraction on an anion exchanger such as DEAE-Cellulose and eluting it, gel-filtrating the eluate, and lyophilizing the filtrate into powder. The hyaluronidase thus obtained has a molecular weight of about 70,000, with isoelectric point of pH 5.2, and enzymatic optical pH ranging 3.6 - 4.0, differing from conventional bovin testicular hyaluronidase. The preparation contains no heterogeneous proteins which cause ill-effect to human body.
Inventors
- 👤 Yasuhiro Mima
- 👤 Masaaki Yamada
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 15:03
CPC Classifications
C; C12; C12N; C12N9/00; C12N9/14; C12N9/24; C12N9/2402; C12N9/2405; C12N9/2408; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S435/00; Y10S435/814; Y10S435/815; Y10S435/816
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
61 words
A human placental hyaluronidase preparation free from hypotensive factors, blood type substances, and hemoprotein, said human placental hyaluronidase having a molecular weight of about 70,000, an isoelectric point of pH about 5.2 and enzymatic optimum pH ranging from 3.6 to 4.0, and being stable for at least 24 hours when kept below 30° C. at pH 6-7 in an aqueous solution.
Claim 2
Dependent Claim
61 words
A human placental hyaluronidase preparation free from hypotensive factors, blood type substances, and hemoprotein, said human placental hyaluronidase having a molecular weight of about 70,000, an isoelectric point of pH about 5.2 and enzymatic optimum pH ranging from 3.6 to 4.0, and being stable for at least 24 hours when kept below 30° C. at pH 6-7 in an aqueous solution.
Claim 3
Dependent Claim
22 words
A human placental hyaluronidase preparation according to claim 1, wherein the human placental hyaluronidase contained is in the form of lyophilized powder.
Claim 4
Dependent Claim
85 words
A process for preparing a hyaluronidase preparation comprising subjecting a human placental tissue to extraction with an aqueous alkaline solution at a pH of about 7.5 to about 10.5, harvesting globulin fraction from the extract, contacting the globulin fraction with an anion exchanger equilibrated with about 0.005 M to about 0.01 M buffer at a pH of about 6.0 to about 8.5 and eluting hyaluronidase adsorbed with a buffer having an increased molarity and/or a lowered pH, and subjecting thus obtained hyaluronidase fraction to gel-filtration.
Claim 5
Dependent Claim
85 words
A process for preparing a hyaluronidase preparation comprising subjecting a human placental tissue to extraction with an aqueous alkaline solution at a pH of about 7.5 to about 10.5, harvesting globulin fraction from the extract, contacting the globulin fraction with an anion exchanger equilibrated with about 0.005 M to about 0.01 M buffer at a pH of about 6.0 to about 8.5 and eluting hyaluronidase adsorbed with a buffer having an increased molarity and/or a lowered pH, and subjecting thus obtained hyaluronidase fraction to gel-filtration.
Claim 6
Dependent Claim
64 words
The process for preparing a hyaluronidase preparation according to claim 3, wherein before being contacted with the anion exchanger the globulin fraction is contacted with a cation exchanger equilibrated with about 0.01 M to about 0.05 M buffer at a pH of about 5 to about 7 to pass through a partially purified hyaluronidase fraction which is to be contacted with the anion exchanger.
Claim 7
Dependent Claim
63 words
The process for preparing a hyaluronidase preparation according to claim 3, wherein before being contacted with the anion exchanger the globulin fraction is contacted with an anion exchanger equilibrated with about 0.1 M to about 0.2 M buffer at a pH of about 6.0 to about 7.0 to pass through a partially purified hyaluronidase which is to be contacted with the anion exchanger.
Claim 8
Dependent Claim
47 words
The process for preparing a hyaluronidase preparation according to claim 3, wherein the harvesting of the globulin fraction is effected by salting out fractionation with ammonium sulfate and collecting a precipitate of up to 40 to 55% saturation at a pH of about 6.5 to about 7.5.
Claim 9
Dependent Claim
45 words
The process for preparing a hyaluronidase preparation according to claim 3, wherein the harvesting of the globulin fraction is effected by precipitation with a water-soluble alcohol and collecting a precipitate of up to 20 to 25% saturation at a pH of about 6.5 to 8.5.
Claim 10
Dependent Claim
27 words
The process for preparing a hyaluronidase preparation according to claim 3, wherein the whole procedures are effected at a temperature of below 5° C in wet state.
Claim 11
Dependent Claim
37 words
The process for preparing a hyaluronidase preparation according to claim 3, wherein the anion exchanger is a polysaccharide gel with basic groups, a styrene-divinylbenzene copolymer gel with basic groups or a phenol formaldehyde resin with basic groups.
Claim 12
Dependent Claim
40 words
The process for preparing a hyaluronidase preparation according to claim 3, wherein the anion exchanger is a diethylaminoethyl dextran gel (DEAE-Sephadex), a diethylaminoethyl cellulose (DEAE-Cellulose), a quaternary ammonium-styrene DVB matrix (Dowex 1), or a phenol formaldehyde polyamine resin (Amberlite XE).
Claim 13
Dependent Claim
55 words
The process for preparing a hyaluronidase preparation according to claim 3, wherein the gelfiltration is effected by passing the hyaluronidase fraction through a highly cross-linked polysaccharide gel molecular sieving such as Sephadex G-150 and Sephadex G-200, a polyacrylamide gel molecular sieving such as Biogel P-30, or an agarose gel molecular sieving such as Sepharose 6-B.
Claim 14
Dependent Claim
30 words
The process for preparing a hyaluronidase preparation according to claim 4, wherein the cation exchanger is a carboxymethyl-cellulose (CM-Cellulose), carboxymethyl dextran (CM-Sephadex), or a carboxylic methacrylic acid-divinylbenzene copolymer (Amberlite IRC-50).
Claim 15
Dependent Claim
24 words
The process for preparing a hyaluronidase preparation according to claim 5, wherein the anion exchanger is same as the anion exchanger in claim 1.
Claim 16
Dependent Claim
11 words
A hyaluronidase preparation prepared by the process according to claim 3.
References Cited (Backward Citations)
US2808362A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1979-03-23 | 1979-09-22 | 1980-03-23 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1983-03-23 | 1983-09-22 | 1984-03-23 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1987-03-23 | 1987-09-22 | 1988-03-23 | $7700.00 | Window Closed / Lapsed |